Felipe Duran
Fortune : 68 351 $ au 31/05/2026
Fortune : 68 351 $ au 31/05/2026
Felipe Duran is currently Chief Financial Officer at iBio, Inc. since 2023.
Formerly, Mr. Duran was Chief Financial Officer-Lupin Latin America at Lupin Pharmaceuticals, Inc. from 2016 to 2021 and Manager-Financial Planning & Analysis at Noven Pharmaceuticals, Inc. Education includes undergraduate and MBA degrees from the University of Miami.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IBIO, INC. 0,1% | 19/03/2026 | 35 974 ( 0,1% ) | 68 351 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| IBIO, INC. | Directeur Financier/CFO | 13/02/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes generic formulations, biotechnology products & APIs | Directeur Financier/CFO | 01/05/2021 |
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development, manufacture, marketing and sale of transdermal pharmaceutical products | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Noven Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research, development, manufacture, marketing and sale of transdermal pharmaceutical products | Commercial Services |
University of Miami
University of Miami Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Lupin Pharmaceuticals, Inc.
Lupin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes generic formulations, biotechnology products & APIs | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national